CCL5 is recognised by a range of chemokine receptors that are maintained on ex vivo stimulated T cells such as CCR1, CCR3, and CCR5, making CCL5 a good candidate for tumour-specific expression to target adoptively transferred lymphocyte migration [74]. The gene discussed is CCL5; the disease is neoplasm.